RE: According to AI3 Feb 2026 15:11
"
Related Party Transaction
As announced on 1 August 2024, the Company entered into a consultancy agreement effective from 1 January 2022, with Infusion (2009) Limited (“Infusion”), an English company controlled by Professor Francesco Gardin, the Company’s chairman and chief executive. Under the consultancy agreement, Infusion provides the services of Professor Gardin as chief research officer.
The Company’s board (excluding Professor Gardin), to reflect the level and nature of Professor Gardin’s input into the Company’s research programmes, agreed to increase the monthly consultancy fee payable to Infusion from £12,500 to £16,250 with effect from 1 January 2024. The Company also awarded an additional fee of £100,000 to reflect the contribution made by Professor Gardin to the Company’s research programmes during 2024.
In addition, Professor Gardin assigned to Infusion his rights to a payment of 10% commission in respect of funds recovered from SIPIEM and Sosushi, Mediapolis and Geosim (four of the Company's legacy assets), as set out in Francesco Gardin’s original July 2015 letter of appointment, reconfirmed in April 2021.
The awards made under the consultancy agreement and the assignment are treated as related party transactions under the AIM Rule 13 of the AIM Rules for Companies. With the exception of Francesco Gardin, who is involved in the transaction as a related party, the directors of the Company consider, having consulted with the Company’s nominated adviser, that the terms of the transactions are fair and reasonable insofar as its shareholders are concerned"
https://www.londonstockexchange.com/news-article/QBT/final-results/17100247
If in doubt ask AI
"where did the Total Yearly Compensation of €41,000 come from
The figure of €41,000 (approximately £35,000) represents the reported cash-based total compensation for Professor Francesco Gardin as disclosed in the company's financial profile and executive pay reports for the 2024 period.
While this figure appears small relative to the high-value R&D he oversees, the breakdown explains the discrepancy between "reported" annual pay and his actual earnings:
Prorated or Deferred Reporting: Annual reports often reflect the actual cash disbursed within a specific financial calendar window. For example, Yahoo Finance and Simply Wall St report his direct pay as £35,530 (approx. €41k).
Consultancy-Based Structure: Most of Gardin's compensation is paid as "consultancy fees" to his private firm, Infusion 2002 Limited. In some filings, these are categorized separately from "Director Pay," leading to different figures in public financial summaries.
Historical Context: In previous years, these consultancy fees were much higher (e.g., €288,000 in 2023). The lower €41,000 reported for the 2024 period may reflect a specific reporting period or a temporary shift in how his fees were accounted for before the board-approved increase to £16,250/month in early 2